MPR

FDA Approves New Dosage Strength of Biosimilar Omlyclo

Omlyclo was originally approved in March 2025 in 2 single-dose prefilled syringe strengths: 75mg/0.5mL and 150mg/mL.
MPR

Recommendations Developed for Radiation Therapy for Gastric Cancer

HealthDay News — In a practice guideline issued by the American Society for Radiation Oncology and published online November 17 in Practical Radiation Oncology, recommendations are presented for the ...
MPR

Almost 70% of Medicaid Enrollees With Opioid Use Disorder Do Not Receive Meds

HealthDay News — More than 69% of Medicaid enrollees with a new diagnosis of opioid use disorder (OUD) do not receive treatment within 180 days, according to a study published online November 23 in ...
MPR

FDA Memo Claims COVID Vaccine Tied to 10 Child Deaths

HealthDay News — A confidential internal memo from the US Food and Drug Administration (FDA) is creating new controversy around vaccine safety after an agency official said the COVID-19 vaccine may ...
MPR

WHO: Long-Term GLP-1 Therapies Recommended for Adults With Obesity

Intensive behavioral therapy also recommended, including setting physical exercise and diet goals, energy intake restriction, weekly counseling.
MPR

Epigenetic Regulator Fast Tracked for Small Fiber Neuropathy

ST-503 is a one-time dose, investigational epigenetic regulator that specifically targets and silences the SCN9A gene.